1-12 of 12
Adam Giza
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Clinical Trials & Observations
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2024) 144 (3): 272–282.
https://doi.org/10.1182/blood.2023022730
Published: 2024
Includes: Supplemental data
Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Clinical Trials & Observations
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon Kater, Julie Dubois, Michael Gregor, Philipp Bernhard Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek
Journal: Blood
Blood (2024) 143 (25): 2588–2598.
https://doi.org/10.1182/blood.2023022564
Published: 2024
Includes: Supplemental data
Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Moritz Furstenau, Adam Giza, Christof Schneider, Eugen Tausch, Sandra Robrecht, Matthias Ritgen, Jörg Bittenbring, Holger F. Hebart, Björn Schöttker, Anna Lena Illert, Ullrich Graeven, Andrea Stoltefuss, Bernhard Heinrich, Robert Eckert, Anna-Maria Fink, Janina Stumpf, Florian Simon, Kirsten Fischer, Othman Al-Sawaf, Petra Langerbeins, Fanni Kleinert, Jonathan Weiss, Karl-Anton Kreuzer, Anke Schilhabel, Monika Brüggemann, Barbara F. Eichhorst, Stephan Stilgenbauer, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1897.
https://doi.org/10.1182/blood-2023-173707
Published: 2023
Journal Articles

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Armin Riecke, Christof Schneider, Billy Jebaraj, Hassan Jumaa, Marc Young, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer, Eugen Tausch
Journal: Blood
Blood (2023) 142 (Supplement 1): 1903.
https://doi.org/10.1182/blood-2023-179767
Published: 2023
Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Moritz Furstenau, Adam Giza, Anna-Maria Fink, Sandra Robrecht, Jonathan Weiss, Fanni Kleinert, Christof Schneider, Eugen Tausch, Kirsten Fischer, Petra Langerbeins, Othman Al-Sawaf, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 203.
https://doi.org/10.1182/blood-2023-173708
Published: 2023
Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 199.
https://doi.org/10.1182/blood-2023-180558
Published: 2023
Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia Von Tresckow, Anna Maria Fink, Florian Simon, Eugen Tausch, Christof Schneider, Liliya Sivcheva, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah R. Kilfoyle, Gunnar Juliusson, Caspar Da Cunha-Bang, Thomas Illmer, Michael Gregor, Patrick Thornton, Ann Janssens, Tamar Tadmor, Vesa Lindström, Philipp Bernhard Staber, Mark-David Levin, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Stephan Stilgenbauer, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4639.
https://doi.org/10.1182/blood-2023-188827
Published: 2023
Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Clinical Trials & Observations
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Othman Al-Sawaf, Karl-Anton Kreuzer, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (11): 961–972.
https://doi.org/10.1182/blood.2023020013
Published: 2023
Includes: Supplemental data
Journal Articles

Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

Nadine Kutsch, Anna Maria Fink, Anno Federhen, Adam Giza, Sandra Robrecht, Janina Stumpf, Andrea Stoltefuß, Ursula Vehling-Kaiser, Michael Koenigsmann, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Thomas Illmer, Rudolf Schlag, Steffen Dörfel, Tobias Gaska, Michael G. Kiehl, Kirsten Fischer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 140 (Supplement 1): 9879–9881.
https://doi.org/10.1182/blood-2022-169956
Published: 2022
Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia Von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Furstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 834–836.
https://doi.org/10.1182/blood-2022-163245
Published: 2022
Journal Articles

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations

Clinical Trials & Observations
Paula Cramer, Eugen Tausch, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Moritz Fürstenau, Petra Langerbeins, Othman Al-Sawaf, Benedikt W. Pelzer, Anna Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (19): 1805–1816.
https://doi.org/10.1182/blood.2020010484
Published: 2021
Includes: Supplemental data
Journal Articles

Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older

Florian Simon, Adam Giza, Sandra Robrecht, Anna-Maria Fink, Paula Cramer, Julia Von Tresckow, Moritz Fürstenau, Valentin Goede, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Clemens-Martin Wendtner, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2021) 138 (Supplement 1): 1552.
https://doi.org/10.1182/blood-2021-150698
Published: 2021